DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

2025-524744-36-00 · tracked via the Priya Life Science EU tracker

Sponsor

Centre Hospitalier Universitaire De Caen Normandie

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Bacterial Infections and Mycoses

Decision date

20/07/2026

Enrollment target

Sites

France

Condition studied

Patients requiring total hip arthroplasty for coxofemoral osteoarthritis

Investigational medicinal product(s)

DOXYCYCLINE BIOGARAN 100 mgcomprimé pelliculé sécableDOXYCYCLINE ARROW 100 mgcomprimé pelliculéDOXYCYCLINE TEVA 100 mgcomprimé sécableDOXYCYCLINE SANDOZ 100 mgcomprimé sécableGRANUDOXY 100 mgcomprimé pelliculé sécable

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

To measure doxycycline penetration in cancellous bone using the cancellous bone concentration/plasmatic concentration ratio

Endpoint detail

To mesure the concentration of Doxycycline in cortical bone using the cortical bone concentration/plasmatic concentration ratio, To measure the concentration of Doxycycline in synovial fluid using the synovial fluid concentration/plasmatic concentration ratio

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524744-36-00 on CTIS ↗ ← All trials in the EU